Noetik, a biotech company, is leveraging AI, specifically transformer models like TARIO-2, to address the high failure rate in cancer clinical trials. Their approach focuses on better matching patients with specific tumor types to existing treatments, rather than discovering new drugs. This strategy has led to a significant $50 million deal with GSK, marking a shift towards licensing AI platforms rather than developing drugs directly. AI
Summary written by gemini-2.5-flash-lite from 2 sources. How we write summaries →
RANK_REASON Biotech company secures a $50M deal with a major pharmaceutical firm for its AI platform.
